Notes Regarding the Gates Foundation Grant and the Manhica Health Center

The Gates Foundation grant

In September 2003 The Gates Foundation donated $168 million for malaria research. Three research grants were funded:
$28 million for research on new prevention strategies
$40 million to the Medicines for Malaria Venture for new drug development
$100 million to the Malaria Vaccine Initiative for vaccine development

This $100 million was an addition to the 1999 $50 million grant from the Gates Foundation to create the Malaria Vaccine Initiative (MVI) at Program for Appropriate Technology in Health (PATH) in Seattle, Washington. A commercial sponsor, GlaxoSmithKline, was also part of this initial grant. MVI is specifically designed to forge partnerships among the diverse players in vaccine development. It identifies promising vaccines and propels them through the development phase and into clinical trials. The additional $100 million for MVI was to further expand the malaria vaccine development pipeline, accelerate the movement of promising vaccine candidates into clinical trials, and address financial and policy barriers to vaccine development.

The Manhica Health Research Center

The Manhica Health Research Center is located in the rural town of Manhica, about 55 miles north of Maputo, the capital of Mozambique. Operated by a partnership between the government of Mozambique and the Hospital Clinic at the University of Barcelona, Spain, this research center is one of the world’s leading institutions for malaria research and currently is holding the world's most advanced clinical trials on a possible malaria vaccine.